Amaero (3DA) investor relations material

Executive summary

• FY2026 marked a transition to commercial scale, with revenue up 376% to $18.1 million, driven by new multi-year supply agreements and expanded production capacity.

• Completed a $72 million capital investment program, doubling titanium powder capacity and commissioning a third EIGA Premium Atomizer.

• Redomiciled to the U.S., aligning with customer base and enabling pursuit of U.S. defense contracts and a potential U.S. IPO.

• Secured major contracts, including a $6.5 million U.S. Department of War award and first BPMI production contract.

• Ended the year with a contracted backlog of $23.1 million and a growing pipeline in defense, space, aviation, and medical markets.

Financial highlights

• Revenue increased 375.9% year-over-year to $18,146,327 (FY2025: $3,812,978).

• Net loss after tax widened 49.4% to $(36,515,350) (FY2025: $(24,434,935)).

• Gross profit was negative at $(4,739,161), reflecting high cost of sales during scale-up.

• Cash and cash equivalents at year-end were $19.4 million.

• No dividends declared or paid.

Outlook and guidance

• FY2027 priorities include executing supply agreements, advancing customer qualifications, commissioning a fourth atomizer and argon recycling system, and progressing toward a U.S. IPO.

• Contracted backlog of $23.1 million, with $8.5 million secured post-year-end.

• Targeting further revenue growth and margin improvement as new capacity comes online.